FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer By Ogkologos - July 15, 2026 9 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas The European Parliament’s Reports Include Several ESMO Asks and Materially Strengthen the European Commission Proposals Under the ‘Health Package’ MOST POPULAR Rapid Genetic Test Could Help Guide Brain Cancer Surgery May 8, 2025 NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration February 28, 2019 New Drugs Raise Old Questions about Treating Cancer during Pregnancy May 25, 2022 England slips further off-track for smokefree 2030 target December 29, 2022 Load more HOT NEWS Combination Therapy for Metastatic Prostate Cancer Helps Some Men Live Longer FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For...
